ArticleResearch square2026
Non-coding Regulatory Variants in ASD (Autism Spectrum Disorders) Disrupt CTCF Domains and Shape Cell-Type-Specific Neurodevelopmental Landscapes Revealed by Single-Cell Analyses and Cortical Organoids.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Background: Autism Spectrum Disorder (ASD) is a complex neurodevelopmental disorder with substantial genetic heterogeneity. While coding variants have been extensively studied, non-coding regulatory variants-which constitute approximately 99% of the human genome-remain largely underexplored. Their functional impact, particularly at the single-cell level and in organoid models, requires further characterization to better understand how these variants contribute to ASD pathogenesis. Methods: We performed targeted sequencing of 85,394 active cis-regulatory elements (cCREs) from ENCODE v2 in 600 samples (200 trios) previously negative for pathogenic coding variants. Using the Sei deep learning framework, we predicted regulatory impact scores for de novo and ultra-rare inherited variants. Gene mapping of regulatory variants was done using the T Gene tool which assigns target genes by integrating expression data. Differential gene expression was assessed using single-nucleus RNA-seq data from ASD and control brains (n = 64 individuals, ~ 600,000) from Wembley et al, 2023 and temporal gene expression dynamics was characterized in human cortical organoids scRNA seq data across four developmental stages (23 days to 6 months) from the Cortical Organoid Atlas (Broad Institute). Results: We identified 164 de novo variants in 103 probands and 53,023 ultra-rare inherited variants in 199 probands. Following Sei-based prioritization, 47 de novo variants in 44 probands and 13,258 inherited variants in 198 probands showed significant regulatory impact score > 1.1. De novo variants were enriched in promoter-like sequences (PLS) (p = 0.02), with 53.19% affecting CTCF-mediated chromatin boundaries. Inherited variants showed significant enrichment for CTCF-binding loss (p = 1.55×10 Conclusions: Our analysis of regulatory variants in ASD indicates that non-coding mutations significantly contribute to ASD risk by disrupting CTCF domains, leading to alterations in cell type-specific gene regulation. Most de novo regulatory mutations predominantly target genes whose expression is dynamic, varying across different cell types and neurodevelopmental stages, whereas inherited regulatory variants affect constitutively expressed genes across multiple cell types, with stable expression throughout development with the exception of CLU. We also found that genes affected by de novo regulatory variants substantially overlap with those harboring pathogenic coding mutations identified in large-scale sequencing studies. These.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.